2. Search Result
Search Result
Results for "

brain imaging

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

13

Fluorescent Dye

3

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

1

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-42110
    Deschloroclozapine
    Maximum Cited Publications
    83 Publications Verification

    		 mAChR Neurological Disease
    Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [ 11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .
    Deschloroclozapine
  • HY-111653
    CycLuc1
    2 Publications Verification

    		 Reactive Oxygen Species (ROS) Others
    CycLuc1 is a blood-brain barrier permeable luciferase substrate that displays near-infrared (NIR) emission with a peak luminescence wavelength of 599 nm. CycLuc1 can be used for in vivo bioluminescence imaging .
    CycLuc1
  • HY-A0168
    Regadenoson
    3 Publications Verification

    CVT-3146

    		 Adenosine Receptor Cardiovascular Disease Cancer
    Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson
  • HY-120947
    AV-105

    		Drug Intermediate Neurological Disease
    AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
    AV-105
  • HY-111263
    NIAD-4
    1 Publications Verification

    		 Fluorescent Dye Amyloid-β Others
    NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM .
    NIAD-4
  • HY-N6664
    Gum arabic

    Arabic gum

    		 Environmental Pollutants Parasite Apoptosis PERK Transmembrane Glycoprotein Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Gum Arabic is an orally active complex branched polysaccharide. Gum Arabic can be isolated from the Acacia senegal tree. Gum Arabic upregulates the expression of maturation markers (CD86, CD40, and CD54), promotes ERK1/2 phosphorylation, and inhibits Apoptosis. Gum Arabic exhibits antimalarial effects against Plasmodium berghei ANKA. Gum Arabic exhibits hepatoprotective, renal, and cardiovascular protective activities. Gum Arabic improves obesity. Gum Arabic is commonly used as a stabilizer and thickener. Gum Arabic can be used in the research of brain tumor imaging .
    Gum arabic
  • HY-W094758A
    4-Di-1-ASP

    		Fluorescent Dye Cancer
    4-Di-1-ASP is a styryl dye used to stain glioma cells in living brain tissue for analysis of cell structure, viability, proliferation and endocytosis, cytokinesis and phagocytosis, as well as for observation of mitochondrial structures in living cells. 4-Di-1-ASP fluoresces green when imaged microscopically (λex /λem = 475/606 nm) .
    4-Di-1-ASP
  • HY-160116
    α-Synuclein aggregate binder 1

    		Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein Neurological Disease
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
    α-Synuclein aggregate binder 1
  • HY-126192
    Pittsburgh Compound B

    PiB; 6-OH-BTA-1

    		 Amyloid-β Neurological Disease
    Pittsburgh Compound B (PiB) is a blood-brain barrier-permeable, specific Aβ deposition PET tracer that binds to Aβ(1-40) fibrils with a Ki value of 678.4 nM. Through click chemical modification (a clickable Pittsburgh Compound B derivative is prepared by introducing a PEG3 linker and an alkynyl group at the 6-hydroxy site of Pittsburgh Compound B, followed by covalent conjugation with azide-labeled fluorescent dyes or affinity tags via copper-catalyzed azide-alkyne cycloaddition (CuAAC)), Pittsburgh Compound B and its conjugates can be used for fluorescence imaging, ultrastructural studies, and enrichment and characterization of Aβ complexes. Pittsburgh Compound B is applicable to Alzheimer's disease research .
    Pittsburgh Compound B
  • HY-153248
    PBR28

    		Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability . PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals .
    PBR28
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Neurological Disease Cancer
    NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3
  • HY-145127
    ETZ

    C3-CA-DTZ

    		 Fluorescent Dye Neurological Disease
    ETZ (C3-CA-DTZ) is a promising luciferase substrate (prosubstrate) activatable in vivo by nonspecific esterase to enhance the brain delivery of the luciferin .
    ETZ
  • HY-122607
    DPA-714

    		Mitochondrial Metabolism TSPO Inflammation/Immunology Cancer
    DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. 18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .
    DPA-714
  • HY-103169
    SCH442416
    2 Publications Verification

    		 Adenosine Receptor Neurological Disease
    SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain .
    SCH442416
  • HY-101183
    THK5351

    		Tau Protein Neurological Disease
    THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
    THK5351
  • HY-400882
    Tosylate-DPA-714

    		Drug Derivative Drug Intermediate TSPO Neurological Disease Inflammation/Immunology
    Tosylate-DPA-714 is a GMP-grade precursor for the radiosynthesis of DPA-714 (HY-122607). It crosses the blood-brain barrier and exhibits steroidogenic activity. DPA-714 is a specific ligand for the 18 kDa translocator protein (TSPO) with a Ki of 7.0 nM. Tosylate-DPA-714 is safe and does not bind to central benzodiazepine receptors (benzodiazepine receptor). As a radiolabeling precursor, Tosylate-DPA-714 reacts with 18F via nucleophilic aliphatic substitution to form 18F-DPA-714, enabling specific targeted binding to TSPO. 18F-DPA-714 accurately reflects the level of neuroinflammation mediated by microglial activation, and is used for PET molecular imaging of neurological diseases such as Alzheimer's disease and multiple sclerosis .
    Tosylate-DPA-714
  • HY-136201
    Sodium Glucoheptonate

    		Biochemical Assay Reagents Cancer
    Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection .
    Sodium Glucoheptonate
  • HY-126369
    Exametazime

    HM-PAO

    		 Biochemical Assay Reagents Others
    Exametazime (HM-PAO) is a lipophilic agent used for the preparation of brain imaging radiopharmaceuticals. 99Tcm-Exametazime is an effective in vitro leukocyte labeling agent .
    Exametazime
  • HY-150209
    MODAG-001

    		Fluorescent Dye Neurological Disease
    MODAG-001 can bind to synuclein fibrils in a rat brain. MODAG-001 is a candidate α-syn imaging probe .
    MODAG-001
  • HY-D1704
    Bodipy TMR-X muscimol

    		GABA Receptor Neurological Disease
    Bodipy TMR-X muscimol is a Bodipy labeled Muscimol (HY-N2313) (Ex=543 nm, Em=572 nm). Muscimol is a GABAA agonist. Bodipy TMR-X muscimol can be used for imaging the spread of reversible brain inactivations .
    Bodipy TMR-X muscimol
  • HY-W338446
    BF-170

    		Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-173291
    Tau ligand-1

    		Tau Protein Neurological Disease
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier . In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM . Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system .
    Tau ligand-1
  • HY-19888
    GSK-1482160

    		P2X Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI) .
    GSK-1482160
  • HY-172205
    CHL2310

    		Cytochrome P450 Cancer
    CHL2310 is the inhibitor for CYP46A1 with an IC50 of 0.11 nM, and a Kd of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive 18F .
    CHL2310
  • HY-165116
    1-1(Z)-Octadecenyl-2-docosahexaenoyl-sn-glycero-3-PE

    18:0p/22:6-PE; C18(Plasm)-22:6-PE; PE(P-18:0/22:6)

    		 Endogenous Metabolite Others
    1-1(Z)-Octadecenyl-2-docosahexaenoyl-sn-glycero-3-PE (18:0p/22:6-PE) is a lipid identified in rat brain tissue by mass spectrometry imaging with specific structural and distribution characteristics, and isomers of different fatty acid chains can be identified by improved methods.
    1-1(Z)-Octadecenyl-2-docosahexaenoyl-sn-glycero-3-PE
  • HY-101182
    THK-5117

    		Microtubule/Tubulin Neurological Disease
    THK-5117, an arylquinoline derivative, displays high binding affinity to tau fibrils with a Ki of 10.5 nM. THK-5117 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD)  brain homogenates. 18F-THK-5117 has the potential to act as a tau imaging PET probe .
    THK-5117
  • HY-171236
    FEKAP

    		Opioid Receptor
    FEKAP is a brain-penetrant and selective kappa opioid receptor (KOR) agonist (Ki = 0.43 nM) which isotope labeled form exhibits excellent imaging properties. 11C-FEKAP can be utilized as a radiotracer for imaging KOR .
    FEKAP
  • HY-112636
    Astrophloxine

    		Amyloid-β Others
    Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice .
    Astrophloxine
  • HY-156842
    MCAAD-3

    		Amyloid-β Neurological Disease
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice .
    MCAAD-3
  • HY-174978
    SK60

    		Isocitrate Dehydrogenase (IDH) Others
    SK60 is a dimethylated derivative of GSK321 (HY-18948) with low nanomolar potency and high selectivity for IDH1R132H (IC50 = 14.5 nM). SK60 can be used as a tracer for brain imaging with the fluorescent label [ 18F] .
    SK60
  • HY-174977
    P2Y12R ligand-1

    		P2Y Receptor Neurological Disease
    P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y12R ligand with a Ki value of 17.1 nM. P2Y12R ligand-1 labeled with [ 18F] can be used in studies of brain PET imaging .
    P2Y12R ligand-1
  • HY-174923
    AZ12943203

    		Biochemical Assay Reagents GSK-3 Neurological Disease
    AZ12943203 (Compound 13e) is a GSK-3 PET radioligand with a Kd of 2.94  nM. AZ12943203 has a significant inhibitory potency toward GSK-3β (IC50 : 4.44 nM), and can specifically bind to GSK-3-rich regions of the rodent brain. AZ12943203 can be used for neurodegenerative diseases imaging, particularly Alzheimer’s disease .
    AZ12943203
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3 TFA
  • HY-147151
    AMCPy

    		Biochemical Assay Reagents Others
    AMCPy is a potent electron paramagnetic resonance (EPR) brain imaging agent, possessing excellent lipophilicity for blood brain barrier (BBB) penetration .
    AMCPy
  • HY-163075
    SYB4

    		Sigma Receptor Others
    SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .
    SYB4
  • HY-101181
    THK-5105

    		Microtubule/Tubulin Neurological Disease
    THK-5105, an arylquinoline derivative, displays high binding affinity to tau fibrils. THK-5105 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD)  brain homogenates. 18F-THK-5105 has the potential to act as a tau imaging PET probe .
    THK-5105
  • HY-153432
    TRV-7019

    		Cholinesterase (ChE) Neurological Disease Cancer
    TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity .
    TRV-7019
  • HY-123788
    BRD5814

    		Dopamine Receptor Neurological Disease
    BRD5814 is a D2R antagonist. BRD5814 can be used in schizophrenia research .
    BRD5814
  • HY-157998
    mG2N001

    		mGluR Src Others
    mG2N001 is a negative allosteric modulator (NAM) (IC50: 93 nM) of the metabotropic glutamate receptor mGluR2 and binds to mGluR2 as an antagonist (Ki: 63 nM). mG2N001 is microparticle- and plasma-stable, and its radioisotope [11C]mG2N001 can be used in PET imaging. [11C]mG2N001 has good brain heterogeneity and brain penetration, and can selectively accumulate in mGluR2-rich regions, producing high-contrast brain images .
    mG2N001
  • HY-136201R
    Sodium Glucoheptonate (Standard)

    		Biochemical Assay Reagents Reference Standards Cancer
    Sodium Glucoheptonate (Standard) is the analytical standard of Sodium Glucoheptonate. This product is intended for research and analytical applications. Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection[1][2].
    Sodium Glucoheptonate (Standard)
  • HY-173383
    DOPE-DOTA sodium

    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt

    		 Biochemical Assay Reagents Inflammation/Immunology Cancer
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-122607R
    DPA-714 (Standard)

    		Mitochondrial Metabolism Inflammation/Immunology Cancer
    DPA-714 (Standard) is the analytical standard of DPA-714. This product is intended for research and analytical applications. DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. 18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .
    DPA-714 (Standard)
  • HY-A0168A
    Regadenoson hydrate

    CVT-3146 hydrate

    		 Adenosine Receptor Cardiovascular Disease
    Regadenoson hydrate (NSC 169186) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson hydrate also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson hydrate
  • HY-155383
    TNIR7-1A

    		Tau Protein Neurological Disease Cancer
    TNIR7-1A is a fused cycloheptatriene–BODIPY derivative that displays properties favorable for near-infrared (NIR) imaging (Ex/Em = 600/774 nm in PBS) with high affinity and specificity to Neurofibrillary tangles (NFTs) in vitro. TNIR7-1A effectively penetrated the blood–brain barrier .
    TNIR7-1A
  • HY-W728451
    URB694

    		FAAH Cardiovascular Disease Neurological Disease
    URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
    URB694
  • HY-A0168R
    Regadenoson (Standard)

    CVT-3146 (Standard)

    		 Reference Standards Adenosine Receptor Cardiovascular Disease
    Regadenoson (Standard) is the analytical standard of Regadenoson. This product is intended for research and analytical applications. Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson (Standard)
  • HY-103169R
    SCH442416 (Standard)

    		Reference Standards Adenosine Receptor Neurological Disease
    SCH442416 (Standard) is the analytical standard of SCH442416. This product is intended for research and analytical applications. SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain .
    SCH442416 (Standard)
  • HY-U00033
    Iomazenil

    		Endogenous Metabolite Neurological Disease
    Iomazenil is a benzodiazepine receptor antagonist with partial inverse agonist activity. Iomazenil can assess the binding potential of central benzodiazepine receptors in the cerebral cortex and may reflect neuronal function in viable tissue. Iomazenil use is associated with improved cognitive function in adult patients with ischemic cerebral pathology after indirect revascularization surgery. Iomazenil demonstrated restoration of benzodiazepine receptor binding potential in the affected hemisphere after surgery on brain SPECT imaging .
    Iomazenil
  • HY-P991654
    SAR228810

    		Amyloid-β Neurological Disease
    SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .
    SAR228810
  • HY-121364
    Bodilisant

    		Histamine Receptor Fluorescent Dye Others
    Bodilisant is a histamine H3 receptor (hH3R) ligand and imaging/labeling agent, with a Ki value of 6.51 nM for hH3R. Bodilisant binds to hH3R to produce strong green fluorescence, localizes to the extracellular membrane without internalization, and generates clear, displaceable fluorescent labeling of hH3R in native human brain tissues. Bodilisant serves as a pharmacological tool to visualize the distribution of hH3R via fluorescence confocal laser scanning microscopy .
    Bodilisant

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: